Skin Substitutes — Coverage and Prior Authorization (Non‑Hospital Outpatient)
Customize your policy alerts
Sign up for all husky_health policy alerts
Know when husky_health releases new policies or updates existing guidance.
Monitor payer policy activity
Rules and prior authorization requirements for use of bioengineered skin and soft tissue substitutes in non-hospital outpatient settings for Connecticut Medicaid (HUSKY Health) providers; focuses on diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs).
No material clinical or coverage changes in this revision.
Coverage criteria for skin substitutes
Medically necessary use for DFUs and VLUs
Covered when ALL of the following are met:
Documentation of wound measurements (pre- and post-treatment), evidence of ongoing standard care, and demonstration of adequate circulation must be submitted with the authorization request.
Subsequent treatment
Subsequent applications considered when ALL of the following are met:
Requests for additional applications beyond 8 in 16 weeks should include rationale and will be reviewed individually; documentation of progressive healing is required.
Simultaneous use of more than one skin substitute is not medically necessary and is not consistent with current standards of practice. Retreatment of a wound that is already healed or a wound demonstrating significant improvement (e.g., presence of granulation tissue, epithelialization, and measurable progress toward closure) is not medically necessary. Additionally, the use of skin substitutes for indications other than diabetic foot ulcers (DFUs) or venous leg ulcers (VLUs) in non-hospital outpatient settings is considered investigational and not medically necessary due to insufficient evidence in peer‑reviewed published literature.
The HCPCS code ranges listed in this policy are considered investigational and not medically necessary. Refer to the policy section titled “Codes/Code Ranges Considered Investigational and Not Medically Necessary” for the full list of ranges and the policy note that authorization is based on medical necessity at the time it is issued and is not a guarantee of payment.
The following specific products have been identified as having insufficient evidence to support their use for treatment of DFUs or VLUs in non-hospital outpatient settings and are therefore considered investigational and not medically necessary: Alloskin™ AC; Allowrap® DS/Allowrap® Dry; ArthroFLEX®; Bellacell™ HD; Ez‑Derm®; Helicoll®; Hmatrix®; Interfyl®; Matriderm; Matristem Micromatrix®; and Alloderm™. Other listed skin substitutes for non‑DFU/VLU indications are likewise considered investigational when evidence is lacking.
The policy explicitly identifies multiple HCPCS codes and code ranges as investigational and not medically necessary. Examples include ranges such as A2001‑A2018, A2021‑A2035, Q4100, Q4103‑Q4104, and many subsequent Q‑code ranges listed in the policy. Providers must use the policy’s coding list to confirm whether a specific HCPCS code or code range is considered investigational prior to submission.
Relevant billing and HCPCS/CPT codes
| Q4100 | Skin Substitute, not otherwise specified (Q4100) |
| A2019 | Kerecis omega3 marigen shield per square centimeter. |
| Q4101 | Apligraf per square centimeter. |
| Q4102 | Oasis wound matrix per square centimeter. |
| Q4105 | Integra dermal regeneration template (drt) or Integra OmniGraft dermal regeneration. |
| Q4106 | Dermagraft per square centimeter. |
| Q4107 | Graftjacket per square centimeter. |
| Q4110 | Primatrix per square centimeter. |
| Q4121 | Theraskin per square centimeter. |
| Q4122 | Dermacell, Dermacell awm, or Dermacell awm porous per square centimeter. |
| Q4128 | Flex hd or Allopatch hd per square centimeter. |
Prior authorization, submission, and utilization limits
Prior authorization required for non-hospital outpatient skin substitutes
Prior authorization is required for the use of skin substitutes when provided in all outpatient settings except outpatient hospital; outpatient hospitals should refer to CMAP Addendum B for outpatient hospital coverage and reimbursement guidance.
Prior authorization effective Aug 1, 2025 for covered codes
Prior authorization for the listed skin substitute codes is effective for requests beginning August 1, 2025; requests on or after that date must have an approved prior authorization to be considered under this policy.
Application limits — initial and subsequent
Application limits: initial requests may include up to four (4) applications of an approved skin substitute; subsequent treatment is typically limited and reviewed as described below.
- Initial requests: maximum of four (4) applications if all clinical criteria are met.
- Subsequent treatment: typically limited to a maximum of eight (8) applications over a sixteen (16) week period; exceptions are reviewed case-by-case.
Billing and code-use requirements
Bill and request authorization using the HCPCS codes listed as medically necessary in the policy; codes or code ranges labelled investigational are not medically necessary and require caution to avoid denial.
Required submission materials for prior authorization
Submit a fully completed authorization request via the online web portal, the fully completed Skin Substitute Prior Authorization Request Form, and clinical documentation supporting medical necessity per the Clinical Guideline; for subsequent requests include documentation demonstrating evidence of healing and progressive wound closure.
- 1) Fully completed authorization request via online web portal.
- 2) Fully completed Skin Substitute Prior Authorization Request Form.
- 3) Clinical documentation from the requesting provider supporting medical necessity as outlined in the Clinical Guideline.
- 4) For subsequent requests, documentation supporting continued applications including evidence of healing and progressive wound closure.
Prior authorization and medical necessity definition
Prior authorization is required for covered services and approvals are determined based on the Connecticut definition of medical necessity as used in this policy.
- Medical necessity determinations follow the Connecticut General Statutes definition and the policy's Clinical Guideline.
Authorization is time- and coverage-dependent
Authorization decisions are based on medical necessity at the time the authorization is issued and do not guarantee payment; payment is contingent on the member having active coverage, benefits, and policies in effect at the time of service.
Payment contingent on member eligibility and benefits
Payment for authorized services depends on member eligibility and benefit coverage at time of service; an approved authorization does not override lack of active coverage or applicable benefit limits.
- Providers should verify the member's active coverage and benefits on the service date; authorization alone is not a guarantee of payment.
Clinical and policy background
Bioengineered skin and soft tissue substitutes are materials derived from human, animal, or synthetic sources designed to replace damaged or missing skin or soft tissue, provide a protective barrier, facilitate tissue regeneration, or restore skin function. In the clinical context of this policy, these products are used as an adjunct to standard wound care for chronic, partial‑ or full‑thickness, non‑infected diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs) in non‑hospital outpatient settings when wounds have not adequately responded after at least 4 weeks of documented standard care. Use of these products requires appropriate patient selection, adequate circulation (including ABI >= 0.60 and palpable or Doppler‑confirmed pedal pulses), control of underlying conditions, and continuation of standard care such as offloading for DFUs or compression for VLUs.
Key definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.